• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Selective oestrogen receptor modulators, aromatase inhibitors and the female breast.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Howell, Anthony
    Affiliation
    CRUK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester, UK.
    Issue Date
    2005-08
    
    Metadata
    Show full item record
    Abstract
    PURPOSE OF REVIEW: Tamoxifen has been available for over 20 years and remains the most commonly recognized endocrine therapy. This review was prompted by a wealth of new data on several newer endocrine agents, including selective oestrogen receptor modulators, aromatase inhibitors and a new oestrogen receptor antagonist, fulvestrant, which unlike the selective oestrogen receptor modulators has no oestrogen agonist effects. RECENT FINDINGS: Completed analysis of the 'Arimidex', Tamoxifen, Alone or in Combination trial demonstrated that anastrozole as initial adjuvant therapy significantly improved disease-free survival and time to recurrence compared with tamoxifen, as well as reducing the incidence of contralateral breast cancer deaths. The Italian Tamoxifen Anastrozole trial and the Austrian Breast and Colorectal Cancer Study Group 8/Arimidex Nolvadex 95 trial have indicated that anastrozole may also be beneficial in women who have already received 2-3 years of tamoxifen. Similarly, the Intergroup Exemestane Study demonstrated the efficacy of exemestane in this setting. Women who have completed a full 5-year course of tamoxifen may also benefit from aromatase inhibitor treatment as indicated by the MA 17 trial, which investigated letrozole as extended adjuvant therapy. Fulvestrant is effective in tamoxifen-resistant disease, and phase II trial data suggest that fulvestrant may also be effective following aromatase inhibitor failure. SUMMARY: The introduction of the third-generation aromatase inhibitors has caused a paradigm shift in adjuvant endocrine treatment. Research into the optimal use of selective oestrogen receptor modulators continues and the evidence base for fulvestrant, the first in a new class of endocrine agents, continues to grow, confirming its value in the treatment of hormone-responsive breast cancer.
    Citation
    Selective oestrogen receptor modulators, aromatase inhibitors and the female breast. 2005, 17 (4):429-34 Curr. Opin. Obstet. Gynecol.
    Journal
    Current Opinion in Obstetrics & Gynecology
    URI
    http://hdl.handle.net/10541/75844
    PubMed ID
    15976552
    Type
    Article
    Language
    en
    ISSN
    1040-872X
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    • Authors: Howell A, Howell SJ, Clarke R, Anderson E
    • Issue date: 2001 Dec
    • Are aromatase inhibitors superior to antiestrogens?
    • Authors: Howell A, Buzdar A
    • Issue date: 2005 Feb
    • The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    • Authors: Howell SJ, Johnston SR, Howell A
    • Issue date: 2004 Mar
    • Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
    • Authors: Mouridsen HT, Robert NJ
    • Issue date: 2005 Aug 24
    • Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    • Authors: Jahanzeb M
    • Issue date: 2007 Aug
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.